CMAJ • July 15, 2008; 179 (2). doi:10.1503/cmaj.070256.
© 2008 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Résumé
Right arrow Online Appendices
Right arrow Correction (v179,p802)
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eisenberg, M. J.
Right arrow Articles by Pilote, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eisenberg, M. J., MD MPH
Right arrow Articles by Pilote, L., MD PhD
Related Collections
Right arrow Smoking
Right arrowRelated Articles

Research

Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials

Mark J. Eisenberg, MD MPH, Kristian B. Filion, MSc, Daniel Yavin, BSc, Patrick Bélisle, MSc, Salvatore Mottillo, BSc, Lawrence Joseph, PhD, André Gervais, MD, Jennifer O'Loughlin, PhD, Gilles Paradis, MD MSc, Stephane Rinfret, MD MSc and Louise Pilote, MD PhD

From the Divisions of Cardiology and Clinical Epidemiology (Eisenberg, Filion, Yavin, Mottillo), Sir Mortimer B. Davis Jewish General Hospital and McGill University; the Department of Epidemiology, Biostatistics and Occupational Health (Eisenberg, Filion, Joseph, Paradis, Pilote), McGill University; the Division of Clinical Epidemiology (Filion, Bélisle, Joseph, Pilote), McGill University Health Centre; Agence de la santé et des services sociaux (Gervais), Direction de santé publique; Centre de recherche (O'Loughlin) and Division of Cardiology (Rinfret), Centre hospitalier de l'Université de Montréal; the Department of Social and Preventive Medicine (O'Loughlin), University of Montreal; and the Division of Internal Medicine (Pilote), McGill University Health Centre, Montréal, Que.

Correspondence to: Dr. Mark J. Eisenberg, Divisions of Cardiology and Clinical Epidemiology, Sir Mortimer B. Davis Jewish General Hospital, Ste. A-118, 3755 Cote Ste-Catherine Rd., Montréal QC H3T 1E2; fax 514 340-7564; mark.eisenberg{at}mcgill.ca

Background: Many placebo-controlled trials have demonstrated the efficacy of individual pharmacotherapies approved for smoking cessation. However, few direct or indirect comparisons of such interventions have been conducted. We performed a meta-analysis to compare the treatment effects of 7 approved pharmacologic interventions for smoking cessation.

Methods: We searched the US Centers for Disease Control and Prevention's Tobacco Information and Prevention database as well as MEDLINE, EMBASE and the Cochrane Library for published reports of placebo-controlled, double-blind randomized controlled trials of pharmacotherapies for smoking cessation. We included studies that reported biochemically validated measures of abstinence at 6 and 12 months. We used a hierarchical Bayesian random-effects model to summarize the results for each intervention.

Results: We identified 70 published reports of 69 trials involving a total of 32 908 patients. Six of the 7 pharmacotherapies studied were found to be more efficacious than placebo: varenicline (odds ratio [OR] 2.41, 95% credible interval [CrI] 1.91–3.12), nicotine nasal spray (OR 2.37, 95% CrI 1.12–5.13), bupropion (OR 2.07, 95% CrI 1.73–2.55), transdermal nicotine (OR 2.07, 95% CrI 1.69–2.62), nicotine tablet (OR 2.06, 95% CrI 1.12–5.13) and nicotine gum (OR 1.71, 95% CrI 1.35–2.21). Similar results were obtained regardless of which measure of abstinence was used. Although the point estimate favoured nicotine inhaler over placebo (OR 2.17), these results were not conclusive because the credible interval included unity (95% CrI 0.95–5.43). When all 7 interventions were included in the same model, all were more efficacious than placebo. In our analysis of data from the varenicline trials that included bupropion control arms, we found that varenicline was superior to bupropion (OR 2.18, 95% CrI 1.09–4.08).

Interpretation: Varenicline, bupropion and the 5 nicotine replacement therapies were all more efficacious than placebo at promoting smoking abstinence at 6 and 12 months.


Related Articles

Highlights
Can. Med. Assoc. J. 2008 179: 113. [Full Text] [PDF]

Dans ce numéro
Can. Med. Assoc. J. 2008 179: 115. [Full Text] [PDF]

The missing link in tobacco control
Jon O. Ebbert, MD and J. Taylor Hays, MD
Can. Med. Assoc. J. 2008 179: 123-124. [Full Text] [PDF]

Intentions of smokers to use free nicotine replacement therapy
John A. Cunningham, PhD and Peter L. Selby, MBBS
Can. Med. Assoc. J. 2008 179: 145-146. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 CMAJHome page
J. P.A. Ioannidis
Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses
Can. Med. Assoc. J., October 13, 2009; 181(8): 488 - 493.
[Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
J. T. Hays, J. O. Ebbert, and A. Sood
Treating Tobacco Dependence in Light of the 2008 US Department of Health and Human Services Clinical Practice Guideline
Mayo Clin. Proc., August 1, 2009; 84(8): 730 - 736.
[Abstract] [Full Text] [PDF]

Home page
 ESC Textbook of Cardiovascular MedicineHome page
F. Crea, P. G. Camici, R. De Caterina, and G. A. Lanza
CHAPTER 17 Chronic Ischaemic Heart Disease
ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
K. B. Filion MSc, P. Belisle MSc, L. Joseph PhD, G. Paradis MD MSc, S. Rinfret MD MSc, and M. J. Eisenberg MD MPH
Smoking cessation trials
Can. Med. Assoc. J., November 4, 2008; 179(10): 1038 - 1038.
[Full Text] [PDF]

Home page
 CMAJHome page
J. R. Polito JD
Smoking cessation trials
Can. Med. Assoc. J., November 4, 2008; 179(10): 1037 - 1038.
[Full Text] [PDF]

Home page
 CMAJHome page
J. O. Ebbert MD and J. T. Hays MD
The missing link in tobacco control
Can. Med. Assoc. J., July 15, 2008; 179(2): 123 - 124.
[Full Text] [PDF]

eLetters:

Read all eLetters

Meta-analysis rooted in expectations not science
John R. Polito
CMAJ, 29 Jul 2008 [Full text]
Comparison varenicline-bupropion
Emile Saad
CMAJ, 11 Aug 2008 [Full text]
Pharmacotherapy for smoking cessation
Joan M Brewster
CMAJ, 29 Jul 2008 [Full text]
Two warnings and a correction
Piersante Sestini
CMAJ, 11 Aug 2008 [Full text]
Three of the authors respond to Piersante Sestini
Kristian B. Filion
CMAJ, 11 Aug 2008 [Full text]
Re: Three of the authors respond to Piersante Sestini
Piersante Sestini
CMAJ, 11 Sep 2008 [Full text]
Race and smoking cessation therapies
Craig S McLachlan
CMAJ, 22 Aug 2008 [Full text]
Response to Letter “Pharmacotherapy for Smoking Cessation”
Kristian B. Filion
CMAJ, 10 Sep 2008 [Full text]
Response to Letter “Meta-analysis Rooted in Expectations Not Science”
Kristian B. Filion
CMAJ, 10 Sep 2008 [Full text]
Race and Smoking Cessation Therapies
Kristian B. Filion
CMAJ, 10 Sep 2008 [Full text]
Response to Letter from Dr. Sestini
Mark J Eisenberg
CMAJ, 11 Sep 2008 [Full text]